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ability of preceptors to focus on the knowledge, skills, and abilities
required in the ﬁrst year of practice on a BMT unit.
Before development of the CBO, experienced staff nurses on the
BMT unit identiﬁed a lack of consistency in novice BMT staff
nurses in performance of key BMT skills and assessments. Con-
versely, the group of novice BMT nurses identiﬁed frustration with
a lack of a consistent approach by preceptors in the teaching of key
BMT skills and assessments. In response to these concerns, a core
group of experienced BMT nurses developed a CBO speciﬁc to
BMT using an evidence-based approach.
Ten core competencies with corresponding measurable criteria
were identiﬁed for the BMT CBO. Competency veriﬁcation meth-
ods used by preceptors include observation, return demonstration,
discussion, mock events, and self-assessment by the orientee. In
addition to the CBO, a BMT skills checklist was developed for
competency validation of a core set of technical skills identiﬁed as
essential for an orientee to be deemed competent to practice in the
BMT setting. The BMT-speciﬁc CBO resulted in a signiﬁcant
improvement in performance by new orientees, a smoother tran-
sition into the novice BMT nurse role, as well as a positive re-
sponse by experienced staff members regarding the performance of
novice BMT nurses.
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HUMAN HERPESVIRUS 6 (HHV6) INFECTION AND REACTIVATION IN
THE PEDIATRIC PATIENT AFTER ALLOGENEIC TRANSPLANTATION:
NURSING EDUCATION AND IMPLICATIONS FOR PATIENT CARE
Sickel, A.D., McConnell, C.L. The Children’s Hospital, Denver, CO.
Human herpesvirus 6 (HHV6) is a relatively mild viral infection
that causes roseola in infants and young children. In the immuno-
competent child, HHV6 is characterized by fevers and a rash and
generally resolves without medical treatment. In recent years, how-
ever, there has been an increase in detection of HHV6 in immu-
nocompromised patients, particularly in the pediatric bone marrow
transplantation population. The pediatric stem cell transplantation
nurse should be familiar with assessment, treatment options, and
diagnostic testing associated with HHV6 infection. This virus may
be a serious life-threatening pathogen in this patient population.
HHV6 infection may result from reactivation of latent virus in the
patient’s own blood or cerebrospinal ﬂuid, or it may be acquired
from the latent virus in the mononuclear cells of the donor’s
marrow after transplantation. Pretransplantation treatment regi-
mens, such as total body irradiation, antithymocyte globulin, and
CD3-speciﬁc monoclonal antibodies, may trigger viral reactivation
in the recipient. HHV6 has been associated with many symptoms,
including fevers, GVHD-like rash, invasive fungal infections, in-
terstitial pneumonia, graft failure, and encephalopathic symptoms.
The literature suggests that ganciclovir, phosphonoformate, and
cidofovir have an inhibitory effect against HHV6; however, there
are no conclusive studies on the efﬁcacy of these treatments.
Fortunately, very sensitive quantitative PCRs for HHV6 can be
used to monitor the response to antiviral therapy. Additionally, the
ability to give therapeutic doses of these drugs may be limited by
organ toxicity from previous nephrotoxic and marrow suppressive
medications. A case study will be used to describe the course of a
patient who becomes symptomatic from HHV6 reactivation after
an allogeneic cord blood transplantation.
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MANAGEMENT OF CYTOMEGALOVIRUS IN THE PEDIATRIC BONE MAR-
ROW/STEM CELL TRANSPLANTATION POPULATION
Stanton, T.J., Martin, P.L., Talbert, G. Duke University Medical
Center, Durham, NC.
Children undergoing stem cell and bone marrow transplantation
are at signiﬁcant risk for acquiring infections related to their
prolonged immunosuppression. Herpesviruses, in particular cyto-
megalovirus (CMV), continue to be a major complication for bone
marrow transplantation (BMT) patients, because this virus threat-
ens the survival both of the patient and the graft. Usually BMT
patients are either CMV before transplantation and have reacti-
vation of the infection once immunosuppression occurs, or they
acquire CMV through the transfusion of CMV blood products.
CMV usually attacks the lungs, causing CMV pneumonia which
occurs in approximately 20% of BMT patients. The liver, eyes, and
intestinal tract can also be affected by CMV infections. Early
detection and treatment of CMV is essential in decreasing mor-
bidity and mortality for the BMT patient. The Duke Pediatric
Bone Marrow/Stem Cell Transplant Program has developed an
effective approach for detecting and combating CMV infections.
The implementation of this approach has improved outcomes for
patients who develop CMV infections during the BMT process.
Further research and advances in pharmacology are imperative to
continuing to improve survival rates for BMT patients with active
CMV infections.
The purpose of this abstract is to detail the approach used by the
Duke Pediatric BMT/SCT program, including (1) identifying pa-
tients’ CMV status pretransplantation; (2) determining appropriate
prophylactic antiviral treatment based on patients’ renal function
and engraftment status; (3) monitoring all inpatients’ CMV status
weekly; (4) appropriately changing antiviral treatment based on
weekly CMV results; (5) adapting and altering treatment as needed
based on patients’ renal function and engraftment status; and (6)
continuing to monitor patients’ CMV status for 9 months post-
transplantation.
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CURRENT THERAPIES UTILIZED IN THE TREATMENT OF THE PEDIAT-
RIC NEUROBLASTOMA PATIENT
Gurganus, K.J., Frey, M.A., Driscoll, T. Duke University Medical
Center, Durham, NC.
Neuroblastoma is the most common tumor diagnosed in children
under age 1 year. This disease is a cancer of the sympathetic
nervous system that presents as a lump or mass in the abdomen or
around the spinal cord in the chest, neck, or pelvis. Neuroblastoma
is often present at birth, but often is not diagnosed until much later
when the child begins to manifest signs of the disease. Unfortu-
nately, the majority of cases (73%) of neuroblastoma have often
metastasized by the time of diagnosis. The most common present-
ing signs and symptoms include a lump or mass in the abdomen,
neck, or chest; bulging eyes, bone pain; petechiae; and weakness or
paralyisis. Diagnostic studies are completed, the disease is staged,
and the patient is referred for treatment. The prognosis and treat-
ment options depend on the patient’s age at diagnosis, stage of the
cancer, and histology of the tumor. Initial treatment options are
fairly standardized and include surgery and chemotherapy. The
purpose of this abstract is to describe the new treatment modalities
that are currently being used in children with this disease. The
Duke Pediatric Stem Cell Transplant Program is offering increas-
ing numbers of children new and experimental therapies used in
conjunction with autologous marrow transplantation. These ther-
apies include monoclonal antibodies; 1–131 mIBG, sometimes
done in conjunction with chemotherapy; tandem transplantation;
and fenretinide (a vitamin A derivative).
This poster will also include an overall summary of the disease,
treatment options, and statistics regarding survival rates and prog-
nosis. The individual treatments options, as well as nursing con-
siderations in the care of these children, will be presented.
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IMPROVING SKIN CARE OF THE PEDIATRIC BONE MARROW AND STEM
CELL TRANSPLANTATION PATIENT
Smith, M.L., Frey, M.A. Duke University Medical Center, Durham,
NC.
Infection remains the leading cause of mortality and morbidity in
the immunocompromised patient. The risk of infection is dramat-
ically increased when the body’s basic defenses are altered and lack
normal infection-ﬁghting capabilities. The skin is the largest organ
of the body and the most frequently affected. Patients undergoing
chemotherapy, radiation, and/or marrow ablation (bone marrow/
stem cell transplantation) are at even greater risk for life-threaten-
ing as a result of skin breakdown. Additional insults, such as
graft-versus-host disease, engraftment, respiratory and systemic
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